Rising cost of anticancer drugs in Australia

Internal Medicine Journal

Volumn 44, Issue 5, 2014, Pages 458-463

  Karikios, D J ^a   Schofield, D ^a   Salkeld, G ^b   Mann, K P ^a   Trotman, J ^a   Stockler, M R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cancer; Drug cost; Healthcare cost; Pharmaceutical benefit scheme

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; AUSTRALIA; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG COST; HEALTH CARE COST; HEALTH CARE SYSTEM; LUNG CANCER; MYELOMA; PRESCRIPTION; PRIORITY JOURNAL; DRUG UTILIZATION; ECONOMIC ASPECT; ECONOMICS; HEALTH INSURANCE; HUMAN; NEOPLASMS; SUPPLY AND DISTRIBUTION; TRENDS;

ANTINEOPLASTIC AGENTS; AUSTRALIA; DRUG COSTS; DRUG UTILIZATION; HUMANS; INFLATION, ECONOMIC; INSURANCE, PHARMACEUTICAL SERVICES; NEOPLASMS;

EID: 84899997065     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12399     Document Type: Article

References (25)

1. Australian Institute of Health and Welfare. Health Expenditure Australia 2010-11. Canberra: AIHW; 2012. [cited 2013 Apr 8]. Available from URL: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737423003
2. Australian Institute of Health and Welfare. Australia's Health 2012. Canberra: AIHW; 2012. [cited 2013 Apr 8]. Available from URL: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737422169
3. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007; 25: 180-186.
4. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E etal. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011; 12: 933-980.
5. Kefford RF. Drug treatment for melanoma: progress, but who pays? [editorial]. Med J Aust 2012; 197: 198-199.
6. Lord E Cancer drugs too costly for PBS. Australian Doctor 2013 [cited 2013 Sep 9]. Available from URL: http://www.australiandoctor.com.au/news/latest-news/.cancer-drugs-too-costly-for-pbs
7. Pharmaceutical Benefits Pricing Authority. Pharmaceutical Benefits Pricing Authority Annual Reports (2000-2010). Canberra: Commonwealth of Australia; 2000-2010. [cited 2013 Apr 8]. Available from URL: http://www.pbs.gov.au/info/industry/pricing/pbs-items/historical/pbpa-annual-reports
8. Pharmaceutical Benefits Scheme. PBS Expenditure and Prescriptions (2003-2012). Canberra: Commonwealth of Australia; 2003-2012. [cited 2013 Apr 8]. Available from URL: http://www.pbs.gov.au/info/browse/statistics#Expenditure
9. Australian Institute of Health and Welfare. Health Expenditure Australia 2009-10. Canberra: AIHW; 2011. [cited 2013 Apr 8]. Available from URL: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737420254
10. Australian Government Department of Health and Ageing. Schedule of Pharmaceutical Benefits. Canberra: Commonwealth of Australia; 2000-2013.
11. Cancer Institute New South Wales. eviQ Cancer Treatments Online. Sydney, NSW: Cancer Institute New South Wales; 2013. [cited 2013 Apr 8]. Available from URL: https://www.eviq.org.au
12. Dranitsaris G, Ortega A, Lubbe MS, Truter I. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe. J Oncol Pharm Pract 2012; 18: 57-67.
13. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044-1048.
14. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009; 360: 626-633.
15. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium - the just price. J Clin Oncol 2013; 31: 3600-3604.
16. Savage P. Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009. J Oncol Pharm Pract 2012; 18: 52-56.
17. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008; 13: 30-37.
18. Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF etal. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 2011; 29: 2543-2549.
19. Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc 2012; 87: 935-943.
20. Clarke PM. Challenges and opportunities for the Pharmaceutical Benefits Scheme. Med J Aust 2012; 196: 153-154.
21. Robertson J, Walkom EJ, Henry DA. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. Aust Health Rev 2009; 33: 192-199.
22. Australian Government Department of Health and Ageing. Revised Arrangements for the Efficient Funding of Chemotherapy Drugs & Streamlined Authority Data Capture. Canberra: Commonwealth of Australia; 2013. [cited 2013 Apr 8]. Available from URL: http://www.pbs.gov.au/info/publication/factsheets/shared/revised-arrangements-for-chemotherapy
23. Soria JC, Blay JY, Spano JP, Pivot X, Coscas Y, Khayat D. Added value of molecular targeted agents in oncology. Ann Oncol 2011; 22: 1703-1716.
24. Chim L, Kelly PJ, Salkeld G, Stockler MR. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Pharmacoeconomics 2010; 28: 463-475.
25. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-319.